CBIO
Crescent Biopharma, Inc.
NASDAQ · USHealthcareBiotechnology
$15.05+2.03%
Price as of Jul 20, 2026
CBIO financials
Crescent Biopharma, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $10.8M | $0.00 | $10.0K | $75.0K |
| Cost of revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $10.8M | $0.00 | $10.0K | $75.0K |
| Operating expenses | $163.5M | $49.9M | $39.3M | $47.5M |
| Operating income | -$152.6M | -$49.9M | -$39.3M | -$47.4M |
| Net income | -$153.9M | -$48.5M | -$36.9M | -$46.7M |
| EBITDA | -$149.7M | -$44.2M | -$39.1M | -$47.2M |
| Basic EPS | $-14.78 | $-1.40 | $-0.58 | $-0.89 |
| Diluted EPS | $-14.78 | $-1.40 | $-0.58 | $-0.89 |
| Balance sheet | ||||
| Cash & equivalents | $213.2M | $34.8M | $41.8M | $47.9M |
| Total assets | $240.3M | $35.6M | $45.3M | $51.8M |
| Total liabilities | $37.3M | $51.1M | $6.9M | $8.9M |
| Stockholders’ equity | $203.0M | -$15.5M | $38.4M | $42.9M |
| Total debt | $1.6M | $37.5M | $808.4K | $918.6K |
| Net debt | -$211.5M | $2.7M | -$41.0M | -$47.0M |
| Cash flow | ||||
| Operating cash flow | -$71.5M | -$31.1M | -$34.9M | -$46.5M |
| Capital expenditure | -$919.0K | -$10.0K | -$21.4K | -$84.2K |
| Free cash flow | -$72.5M | -$31.1M | -$34.9M | -$46.5M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | -$177.0K | $0.00 | $0.00 | $0.00 |